BETHESDA, Md--Whaijen Soo, MD, vice president for virology, Hoffmann-La Roche, told the National Task Force on AIDS Drug Development that the company's protease inhibitor, saquinavir (Invirase), is now ready for phase III trials
GENEVA, Switzerland--A newly established United Nations AIDS program based in Geneva has announced plans to initiate large-scale clinical trials of two HIV vaccines as early as mid-1996, probably in Brazil and Thailand. Dr. Peter Piot, chief of research at the World Health Organization's Global Program on AIDS, will head the new group, which will involve six UN agencies.
Dr. DeAngelis has written a succinct and accurate assessment of management of primary central nervous system lymphoma. Non-AIDS-related primary central nervous system lymphoma is a rare, highly malignant primary brain tumor. However, its incidence is increasing, as are AIDS-related tumors of this type. Patients with primary central nervous system lymphoma usually have widespread infiltration throughout the brain, rendering aggressive resection of no benefit. There is a significant incidence of leptomeningeal and ocular involvement (the latter a "sanctuary site," thus posing a particular therapeutic dilemma).
BETHESDA, Md--As expected, the number of reported AIDS cases increased substantially in 1993 due to the expansion of the surveillance case definition in January of that year, but an adjusted analysis shows only a slight overall increase.
Primary CNS lymphoma is rising in incidence in both the AIDS and non-AIDS populations. It is a non-Hodgkin's lymphoma that usually presents as a brain tumor, but the leptomeninges, eyes, and spinal cord also are
PARIS-Physicians need to make a more concerted effort to consider quality of life issues when devising a management strategy for patients with HIV-infection, an infectious diseases specialist said at a conference on cancer, AIDS, and quality of life, sponsored by UNESCO.